REMARKS

Applicants respectfully request entry of amendments to claims 1-4, 6-10, and 12-14, and new claim 40. Please cancel claims 5 and 11, and withdraw claims 15-39, without prejudice or disclaimer. Support for the amendments can be found throughout the specification, including paragraphs [0006], [0014], [0043], [0045], Table 3, the Sequence Listing, and the originally filed claims and, therefore, do not add new matter.

Applicants submit that pending claims 1-4, 6-10, 12-14, and 40 are in condition for allowance, and respectfully request that the claims as amended be entered.

Restriction Requirement

Applicants wish to thank the Examiner for rejoining the primer pairs and acknowledging Applicants' request for rejoinder of process claims with an allowable product as required by M.P.E.P. §806.05(h).

Rejection Under 35 U.S.C. §112, Second Paragraph

Claims 3-7 and 12 stand rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite. As claim 5 has been canceled, the rejection as applied to this claim is rendered moot.

Applicants have amended the claims, where appropriate, to recite "nucleic acid sequence." The term "sequence," which is what a sequence identifier denotes, is a term of art and would be known to one of skill in the biotechnology art, to which this invention belongs. As such, one of skill in the art would understand the metes and bounds of the claims.

For these reasons, Applicants respectfully request that the rejection be withdrawn.

Rejections Under 35 U.S.C. §102

Claims 1 and 2 stand rejected under 35 U.S.C. §102(b), as allegedly being anticipated by Bohne et al., Blais et al., or Camilli et al.

Applicants traverse the rejection as it might apply to the amended claims, including claims dependent therefrom, for the reasons given below.

The Office Action alleges, in pertinent part, that the cited references teach the elements as recited in the present claims, specifically, that the references teach virulence genes "prfA, pclA, hyl[sic], mpl, plcB, and actA." The instant claims have been amended to recite a specific sequence identifier: i.e., SEQ ID NO: 9. Review of SEQ ID NO: 9 demonstrates that a contiguous reading frame is present within residues 887 to 1500, which delimit a target for PCR amplification using primers defined by SEQ ID NO:26 and SEQ ID NO:27. As a point of reference, the predicted amino acid sequence for this contiguous reading frame is given below:

"VTPLTQLTYFDCSVNPLTELDVSTLSKLTTLHCIQTDLLEIDLTHNTQLIYFQAEGCRKI KELDVTHNTQLYLLDCQAAGITELDLSQNPKLVYLYLNNTELTELDVSHNTKLKSLSCVN AHIQDFSSVGKIPALNNNFEAEGQTITMPKETLTNNSLTIAVSPDLLDQFGNPMNIEPGD GGVYDQATNTITWENLSTDNPAV"

Review of the amino acid sequences available from the National Center for Biotechnology Information (NCBI) for the sequences recited in the Action (see, e.g., Exhibits A-F), show that no significant homology exists between the virulence genes recited in the Action and the predicted amino acid sequence from the contiguous reading frame present within SEQ ID NO: 9. Because the present claims expressly recite a sequence identifier, which is not taught or suggested in the references cited, neither Bohne et al., Blais et al, nor Camilli et al., separately or in combination, anticipate the claimed invention.

As stated in <u>Hybritech Inc. v. Monoclonal Antibody, Inc.</u>, 231 U.S.P.Q. 81 (Fed. Cir. 1986), "It is axiomatic that for prior art to anticipate under 102 it has to meet every element of the claimed invention."

Therefore, because the instant claims recite a sequence identifier which is not taught or suggested in the references cited, the cited references, alone or in combination, do not anticipate the claimed invention.

Failure of the prior art to meet every element of the claimed invention does not meet the standard under §102. For these reasons, Applicants respectfully request that the rejection be withdrawn.

Claims 1-14 stand rejected under 35 U.S.C. §102(b), as allegedly being anticipated by Kunst et al. or Glasner et al. As Claims 5 and 12 have been canceled, the rejection as applied the these claims is rendered moot.

Applicants traverse the rejection as it might apply to the amended claims, including claims dependent therefrom, for the reasons given below.

The Office Action alleges, in pertinent part, that the cited references teaches the elements as recited in the present claims. Glasner et al. is offered to demonstrate the isolation of virulence genes "prfA, pclA, hyl[sic], mpl, plcB, and actA." Again, as stated above, the instant claims have been amended to recite a specific sequence identifier: i.e., SEQ ID NO: 9. Review of SEQ ID NO:9 demonstrates that a contiguous reading frame is present within residues 887 to 1500, which delimit a target for PCR amplification using primers defined by SEQ ID NO:26 and SEQ ID NO:27. As a point of reference, the predicted amino acid sequence for this contiguous reading frame is given below:

[&]quot;VTPLTQLTYFDCSVNPLTELDVSTLSKLTTLHCIQTDLLEIDLTHNTQLIYFQAEGCRKI KELDVTHNTOLYLLDCOAAGITELDLSONPKLVYLYLNNTELTELDVSHNTKLKSLSCVN

Review of the amino acid sequences available from NCBI for the sequences recited in the Action (see, e.g., Exhibits A-F), show that no significant homology exists between the virulence genes recited in the Action and the predicted amino acid sequence from the contiguous reading frame present within SEQ ID NO: 9. Because the present claims expressly recite the sequence identifier, which is not taught or suggested in Glaser et al., the reference does not anticipate the claimed invention.

Regarding Kunst et al., the Office Action states that the claimed sequences, SEQ ID NO: 9, 26, and 27, are disclosed in the reference. While it is not clear as to which search report the Action is referring to in support of the statement that the sequence identifiers are disclosed, the Kunst et al. sequences can be obtained from the PTO website at, for example: http://seqdata.uspto.gov/?pageRequest=viewSequecne&DocID=20040018514&seqID=2870 and http://seqdata.uspto.gov/?pageRequest=viewSequence&DocID=US20040018514A1&seqID=29 09.

Applicants submit that review of SEQ ID NO: 2909 and 2870 demonstrates that these sequences do not anticipate SEQ ID NO: 9, 26, or 27 as claimed.

Exhibits G and H represent the nucleic acid sequences denoted by sequence identifiers 2870 and 2909 of Kunst et al. At minimum, because both SEQ ID NO: 2870 and 2909 have fewer nucleotides than SEQ ID NO: 9 (2556/759 vs. 2640), SEQ ID NO: 2870 and 2909 are not identical to SEQ ID NO: 9, and thus, do not anticipate SEQ ID NO: 9 as claimed.

Further, Applicants submit that there is no teaching in Kunst et al. which would lead one of skill in the art to make the primers as recited. In the same fashion that genomes do not

inherently anticipate isolated structural genes for want of enablement, Kunst et al. do not provide sufficient guidance to specifically identify the primer sequences as claimed (see, e.g., Chester v. Miller, 15 U.S.P.Q.2d 1281 (Fed. Cir. 1990), where the court stated that "[t]o be prior art under section 102(b), the reference must put the anticipating subject matter at issue into the possession of the public through an enabling disclosure."). Both SEQ ID NOS: 2870 (2556 nt) and 2909 (759 nt) are orders of magnitude longer that either SEQ ID NO: 26 (21 nt) or 27 (20 nt). And while Kunst et al. may or may not suggest the use of primers for the detection of *Listeria* contamination, there is no guidance which would direct the skilled artisan to choose the specific primers as claimed among all the possible alternative fragments that comprise SEQ ID NOS: 2870 and/or 2909.

As stated in <u>Hybritech Inc. v. Monoclonal Antibody, Inc.</u>, 231 U.S.P.Q. 81 (Fed. Cir. 1986), "It is axiomatic that for prior art to anticipate under 102 it has to meet every element of the claimed invention."

Therefore, because the instant claims a) recite a sequence identifier which is not taught or suggested in the cited references and b) recite specific primer sequences which would not be enabled by the teachings of the cited references, neither Glasner et al. nor Kunst et al. anticipate the claimed invention.

Failure of the prior art to meet every element of the claimed invention does not meet the standard under §102. For these reasons, Applicants respectfully request that the rejection be withdrawn.

In light of the above, Applicants submit that this application is now in condition for allowance and therefore request favorable consideration. If any issues remain which the Examiner feels may be best resolved through a personal or telephonic interview, the Examiner is respectfully requested to contact Applicants counsel, James M. Heintz at 202.861.4167.

Respectfully submitted,

DLA PIPER US LLP


James M. Heintz

Registration No. 41,828

Daryl A. Basham, Ph.D. Registration No. 45,869


1200 Nineteenth Street, N.W. Washington, D.C. 20036-2412 Telephone No. 202.861.3900 Facsimile No. 202.223.2085

EXHIBIT A




```
CDS
                     1.,237
                     /gene="prfA"
                     /coded_by="X61210.1:274..987"
                     /transl_table=11
                     /db_xref="GOA: P22262"
                     /db xref="InterPro: IPR000595"
                     /db_xref="InterPro: IPR001808"
                     /db_xref="InterPro: IPR011991"
                     /db xref="InterPro:IPR012318"
                     /db_xref="PDB:10MI"
                     /db_xref="PDB:2BEO"
                     /db_xref="PDB:2BGC"
                     /db_xref="UniProtKB/Swiss-Prot: P22262"
ORIGIN
        1 mnaqaeefkk yletngikpk qfhkkelifn qwdpqeycif lydgitklts isengtimnl
       61 qyykgafvim sgfidtetsv gyynlevise qatayvikin elkellsknl thffyvfqtl
      121 qkqvsyslak fndfsingkl gsicgqllil tyvygketpd gikitldnlt mqelgyssgi
      181 ahssavsrii sklkqekviv yknscfyvqn ldylkryapk ldewfylacp atwgkln
//
```

EXHIBIT B




```
1 msalpdttnl aalsipgthd tmsyngdmtw tltkplaqtq tmslyqqlea giryidirak
61 dnlkiyhgpi ylnaslsgvl etitqflkkn pketiimrlk deqnsndsfd yriqpliniy
121 kdyfyttprt dtsnkiptlk dvrgkillls enhtkkplvi nsrkfgmqfg apnqviqddy
181 ngpsvktkfk eivqtayqas kadnklflnh isatsltftp rqyaaalnnk veqfvlnlts
241 ekvrglgili mdfpekqtik niiknnkfn
//
```

EXHIBIT C



```
pfam01447"
                     /db xref="CDD:41495"
     Region
                     360..509
                     /region name="Peptidase_M4_C"
                     /note="Thermolysin metallopeptidase, alpha-helical domain;
                     pfam02868"
                     /db xref="CDD:42809"
     CDS
                     1..510
                     /gene="mpl"
                     /coded_by="DQ054595.1:1..1533"
                     /transl_table=11
ORIGIN
        1 mkskliciim viafqahftm tvkadsvgee klqnntqakk tpadlkalpd sceakdfykn
       61 fkildmtkdk lgvthytlal ssggyltdnd eikvhvtpdn kitfingdlg ggglritngi
      121 kiteknaiek afeaigqsea hvksyvgnpv kekeiilnsr tkrlvynikl ifaepevasw
      181 ivqvdaetga ilkkqnmlse veradthkdf qalgkganrl lqrplhvmki ndlfylvdrt
      241 hkglirtfdl khntdtsfgk vvsnktnmft dpefssavda hfyasevyey yknvhqlesl
      301 dgkggeidsf vhyglncnna fwdgqeilyg dgdkknfkpf scaktivghe lthaviqysa
      361 gleyegqsga lnesfadvfg yfiapnhwli gedvcvrgsr dgrirsikdp dkynqaahmk
      421 dyeslpitee gdwggvhyns gipnkaaynt itklgkekte qlyfralkyy 1tkksqftda
      481 kkalqqaakd lygedaskkv aeaweavgvn
11
```

EXHIBIT D



241 ivnaktkksy lvgnsewkkd tveptgarlr dsqqtlagfl efwskktne

Disclaimer | Write to the Help Desk NCBI | NLM | NIH

EXHIBIT E

```
/region name="ActA"
                     /note="ActA Protein; pfam05058"
                     /db_xref="CDD:44961"
     Region
                     <368..604
                     /region_name="ActA"
                     /note="ActA Protein; pfam05058"
                     /db xref="CDD:44961"
     CDS
                     1..604
                     /gene="actA"
                     /coded_by="DQ309937.1:9..1823"
                     /transl table=11
ORIGIN
        1 mglnrfmram mvvfitanci tinpdiifaa tdsedsslnt deweeektee qpsevntgpr
       61 yetarevssr dikeleksnk vkntnkadli amlkakaekg pninnnnseq tenaaineea
      121 sqadrpaiqv errhpqlpsd saaeikkrrk aiassdsele sltypdkptk vnkkkvakes
      181 vadasesdld ssmqsadest pqplkanqkp ffpkvfkkik dagkwvrdki denpevkkai
      241 vdksaglidq lltkkkseev nasdfppppt deelrlalpe tpmllgfnap tpsepssfef
      301 pppptedele imretapsld ssftsgdlas lrsainrhse nfsdfppipt eeelngrggr
      361 ptseefssmn sgdftddens etteaeidrl adlrdrgtgk hsrnagflpl npfisspvps
      421 ltpkvpkisa palisditkk apfknpsqpl nvfnkktttk tvtkkptpvk tapklaelpa
      481 tkpgetvlre nktpfiekga etnkgsinmp slpvigkeat esdkeemkpg teekmveese
      541 sannangknr sagieegkli aksaedekak eepgnhttli lamlaigvfs lgafikiiql
      601 rknn
11
```

EXHIBIT F



```
61 lqalgvnaen ppayissvay grqvylklst nshstkvkaa fdaavsgksv sgdveltnii
121 knssfkaviy ggsakdevqi idgnlgdlrd ilkkgatfnr etpgvpiayt tnflkdnela
181 viknnseyie ttskaytdgk inidhsggyv aqfniswdei nydpegneiv qhknwsennk
241 sklahftssi ylpgnarnin vyakectgla wewwrtv
```

EXHIBIT G



United States Patent and Trademark Office

Home | Site Index | Search | FAQ | Glossary | Guides | Contacts | eBusiness | eBiz alerts | News | Help

Publication Site for Issued and Published Sequences (PSIPS) PSIPS View Sequence(s): 2870 for 20040018514

Here is the list of the requested sequences.

<210> SEQ ID NO 2870 Sequence ID <211> LENGTH: 2556 No: <212> TYPE: DNA

<213> ORGANISM: Listeria monocytogenes EGDe

Go <400> SEQUENCE: 2870

First Sequence Next Sequence Previous Sequence Sequence

Full Text Publication

PSIPS Home Page NCBI Home PIW and AIW Search Home Page Document Services Division **USPTO Home**

Help Page FAQ

ttgaaaacta ctaaaatagt aattgcctca ttagttagtt taaccatggt ttcaaacccq cttttaacat tcgcagcaac gaatgatgtt attgataata cgacagaaat cactactgat aaagaaacaa gctcaactca accaactata aaaaacacac tcaaagccgg tcaaacacaa agttttaacg actggtttcc tgatgacaat tttgcttcag aggtagcagc agcatttgaa atgcaagcaa ctgacactat cagcgaagaa caactagcta ctctaacaag tctagattgc cataattcat ccataaccga tatgactggt attgaaaaat taactggttt aacaaaatta atttgcacaa gtaacaacat taccaccett gatcttagcc aaaacactaa tttaacttat ctggcatgtg attcaaataa acttacaaac cttgacgtaa ccccgcttac aaaattaacc tacttaaatt gegacaegaa caaacteaca aagttagatg taagteaaaa teeactgtta acttatttaa actgegegeg caacacetta acegaaatag atgteageca caatacacaa ttaaccgagc tagactgcca tttaaataaa aaaatcacca aattagatgt gacaccacaa aataaactac tgaaccgtct aaactgcgac actaataata taactaaact ggacctcaac caaaatattc agctaacttt cctagattgc tccagtaaca aattaaccga aatagatgta accccqctta cacaqttaac atattttgat tgtagcgtaa atcctttaac tgaattagat gtatctacgc tttcaaaatt aactacacta cattgtatac aaacagattt attagaaata gacctaacac acaacacaca attaatatat tttcaagctg aaggatgtag aaaaataaaa gagettgatg teaegeataa tacacaatta tatttattag aetgeeaage egetggtata acagaattgg atctttcaca aaaccctaaa ttagtctatt tgtatttaaa taatactgaa ctaacggaat tagacgtttc ccataacaca aagctgaaaa gtttgtcttg cgtaaatgcg cacatccaag acttetette tgtaggtaaa atteetgeee ttaacaataa ttttgagget qaaqqqcaaa caatcacgat gcctaaagaa actttaacaa acaacagctt gaccattgca gttagccctg atttattaga tcagtttgga aatccgatga atattgaacc gggagacggc ggtgtgtacg accaagcaac aaatacaata acttgggaaa atctcagcac agacaatcca qccqtaacct atactttcac ttccqaaaac ggagctatag taggaaccgt aacaactcca tttqaaqcac ctcaacccat caaaqqaqaa qacqtcacag tacattacct tgatgacaaa ggagaaaaat tggcggatga tgaagtteta agcggtaatt tggacgatec ttatacttet agegeaaaag acateecaga ttatacatta aegaetaete cagataaege aaeeggaaca 1 ttcaccacta ctagccagtc cgtaacgtac gtttacacta aaaacatcgt agccgcagag cctgtaaccg ttaattacgt ggacgatact ggaaaaaacgc tctctccatc cgaaatatta aacggaaatg ttggcgacac ttataacgcc actgccaaac aaatcgacgg ctacacatta tecqceqaac caaccaatqc aactqqacaa ttcacaagca gegegeaaac egteaactat atttacacaa aaaatccaqc ccctgaaaaa ggagttgtag aaattcacta tgttgacgaa gataataaac aacttaactc caccacagaa atttctggaa caataggaga taactacacg actgagecaa aaactatega aggetataeg ttaacaacta cacegggtaa tgeaacegge actttcacca caggcagcca aaccgtgaca tatgtgtata ctaaaaaacat cgaagcagca gagoogataa cagtgaatta cgtggatgot aatggcaaaa cactegotoc atcogaaaca ttaaacggaa acgttggcga cacatataaa gcaactgcca aacaaatcga cggctacaca ttatccgccg aaccaaccaa tgcgactgga caattcacaa gtagcgcaca aactgtcaac tacatttata cgaaaaacac aaacacagat caacctttac caactaaaaa acctacgaac accacaccaa ccaagccatc taatttaaag acaaccgaag tgaaaaaagc ttcagatacc ctaccaaaaa caggcgattc cgcaccatgg aaatcagctc tacttggggt attcctatca tccacagctc tagttatctg gaaaaagaaa aaatag

PSIPS Home | PSIPS Help Page | PSIPS Accessibility Help Page | PSIPS FAQ | PIW and AIW Search Home Page | Document Services Division | NCBI Home

I.HOME | INDEX | SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT

Last Modified: 02/05/2007 09:30:31

EXHIBIT H



United States Patent and Trademark Office

Home | Site Index | Search | FAQ | Glossary | Guides | Contacts | eBusiness | eBiz alerts | News | Help

Publication Site for Issued and Published Sequences (PSIPS) PSIPS View Sequence(s): 2909 for us20040018514

Here is the list of the requested sequences.

Sequence ID No:

Go

Previous <222> LOCATION: (1)..(end)
Sequence <223> OTHER INFORMATION: n can be any nucleotide: a,g,c or t/u

Last <400> SEQUENCE: 2909

Document aatgctcaca tgcaagactt ctctttgtag gtaaaattc

Services Division USPTO Home

Help Page FAQ

PSIPS Home | PSIPS Help Page | PSIPS Accessibility Help Page | PSIPS FAQ |
PIW and AIW Search Home Page | Document Services Division |
NCBI Home

I.HOME | INDEX | SEARCH | BUSINESS | CONTACT US | PRIVACY STATEMENT

Last Modified: 02/05/2007 09:30:15